AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

NCT00326664 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

Childhood Atypical Teratoid/Rhabdoid Tumor
Childhood Central Nervous System Germ Cell Tumor
Childhood Cerebral Anaplastic Astrocytoma
Childhood Cerebral Astrocytoma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood Infratentorial Ependymoma
Childhood Oligodendroglioma
Childhood Spinal Cord Neoplasm
Childhood Supratentorial Ependymoma
Recurrent Childhood Brain Neoplasm
Recurrent Childhood Brain Stem Glioma
Recurrent Childhood Cerebellar Astrocytoma
Recurrent Childhood Cerebral Astrocytoma
Recurrent Childhood Ependymoma
Recurrent Childhood Medulloblastoma
Recurrent Childhood Pineoblastoma
Recurrent Childhood Subependymal Giant Cell Astrocytoma
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Recurrent Childhood Visual Pathway Glioma

Interventions

DRUG: Cediranib Maleate

Sponsor

National Cancer Institute (NCI)